Description
Human B-lymphocyte antigen CD19 gene is a transmembrane protein, also known as CD19 molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3. CD19 is expressed in all B lineage cells. CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. It is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies, such as the target cells for Anti-CD19 CAR T cell killing assay.
The RPMI 8226 cell line is a human multiple myeloma cell line that was established from the peripheral blood of a 61-year-old male patient with multiple myeloma (surface antigen profile: HLA Aw19, B15, B37, Cw2; CD19 -; CD20 -; CD28 +; CD38 +; CD49e +).
This cell line is transformed as CD19 Positive of RPMI 8226 cell line, expressing human B-lymphocyte antigen CD19 (GeneBank# NM_001178098), under the enhanced CMV promoter (suCMV). The following cassette was verified integrated into cell line’s genome:
see details in Product Manual.
Sold at: 1 vial x (2 x 106 cells)/vial, in stock, shipped in a dry-ice package.
Cat# SC100
